- Toward a Better Dialogue Between Neuro-Oncologists and Phase I Investigators
[作者：Massard, C; Sandhu, S; Blanco, M; Papadatos-Pastos, D; Carden, C; De Bono, J; Saran, F; Molife, LR; Kaye, SB; Soria, JC; Banerji, U,期刊：Journal of clinical oncology, 页码：562-563 , 文章类型： Letter，,卷期：2012年30-5]
-
- Treatment of Patients With Advanced Neurofibromatosis Type 2 With Novel Molecularly Targeted Therapies: From Bench to Bedside
[作者：Subbiah, V; Slopis, J; Hong, DS; Ketonen, LM; Hamilton, J; McCutcheon, IE; Kurzrock, R,期刊：Journal of clinical oncology, 页码：E64-E68 , 文章类型： Article，,卷期：2012年30-5]
-
- Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer
[作者：Munster, PN; Moore, AP; Ismail-Khan, R; Cox, CE; Lacevic, M; Gross-King, M; Xu, P; Carter, WB; Minton, SE,期刊：Journal of clinical oncology, 页码：533-538 , 文章类型： Article，,卷期：2012年30-5]
- Purpose Chemotherapy-induced amenorrhea is a serious concern for women undergoing cancer therapy. This prospective randomized trial evaluated the use of gonadotropin-releasing hormone (GnRH) analog triptorelin to preserv...
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
[作者：Roberts, AW; Seymour, JF; Brown, JR; Wierda, WG; Kipps, TJ; Khaw, SL; Carney, DA; He, SZ; Huang, DCS; Xiong, H; Cui, Y; Busman, TA; McKeegan, EM; Krivoshik, AP; Enschede, SH; Humerickhouse, R,期刊：Journal of clinical oncology, 页码：488-496 , 文章类型： Article，,卷期：2012年30-5]
- Purpose BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-x(L) and BCL-w, potently inducing apoptosis ...
- Circulating Invariant Natural Killer T-Cell Numbers Predict Outcome in Head and Neck Squamous Cell Carcinoma: Updated Analysis With 10-Year Follow-Up
[作者：Schneiders, FL; de Bruin, RCG; van den Eertwegh, AJM; Scheper, RJ; Leemans, CR; Brakenhoff, RH; Langendijk, JA; Verheul, HMW; de Gruijl, TD; Molling, JW; van der Vliet, HJ,期刊：Journal of clinical oncology, 页码：567-570 , 文章类型： Letter，,卷期：2012年30-5]
-
- Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer
[作者：Hou, JM; Krebs, MG; Lancashire, L; Sloane, R; Backen, A; Swain, RK; Priest, LJC; Greystoke, A; Zhou, C; Morris, K; Ward, T; Blackhall, FH; Dive, C,期刊：Journal of clinical oncology, 页码：525-532 , 文章类型： Article，,卷期：2012年30-5]
- Purpose Circulating tumor cells (CTCs) may have utility as surrogate biomarkers and "virtual" biopsies. We report the clinical significance and molecular characteristics of CTCs and CTC clusters, termed circulating tumor...
- Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers
[作者：Kurian, AW; Munoz, DF; Rust, P; Schackmann, EA; Smith, M; Clarke, L; Mills, MA; Plevritis, SK,期刊：Journal of clinical oncology, 页码：497-506 , 文章类型： Article，,卷期：2012年30-5]
- Purpose Women with BRCA1 or BRCA2 (BRCA1/2) mutations must choose between prophylactic surgeries and screening to manage their high risks of breast and ovarian cancer, comparing options in terms of cancer incidence, surv...
- Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
[作者：Albiges, L; Oudard, S; Negrier, S; Caty, A; Gravis, G; Joly, F; Duclos, B; Geoffrois, L; Rolland, F; Guillot, A; Laguerre, B; Legouffe, E; Kohser, F; Dietrich, PY; Theodore, CA; Escudier, B,期刊：Journal of clinical oncology, 页码：482-487 , 文章类型： Article，,卷期：2012年30-5]
- Purpose Complete remission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may occur in some patients. It remains a matter of debate whether the...
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
[作者：Choueiri, TK; Ross, RW; Jacobus, S; Vaishampayan, U; Yu, EY; Quinn, DI; Hahn, NM; Hutson, TE; Sonpavde, G; Morrissey, SC; Buckle, GC; Kim, WY; Petrylak, DP; Ryan, CW; Eisenberger, MA; Mortazavi, A; Bubley, GJ; Taplin, ME; Rosenberg, JE; Kantoff, PW,期刊：Journal of clinical oncology, 页码：507-512 , 文章类型： Article，,卷期：2012年30-5]
- Purpose Vandetanib is an oral once-daily tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 and epidermal growth factor receptor. Vandetanib in combination with docetaxel was as...
- Meta-Analysis of Psychosocial Interventions to Reduce Pain in Patients With Cancer
[作者：Gorin, SS; Krebs, P; Badr, H; Janke, EA; Jim, HSL; Spring, B; Mohr, DC; Berendsen, MA; Jacobsen, PB,期刊：Journal of clinical oncology, 页码：539-547 , 文章类型： Review，,卷期：2012年30-5]
- Purpose Pain is one of the most common, burdensome, and feared symptoms experienced by patients with cancer. American Pain Society standards for pain management in cancer recommend both pharmacologic and psychosocial app...
|